21 March 2023 in Journal of Pediatric Endocrinology and Metabolism
Objectives Childhood-onset craniopharyngiomas (CPs) have a high incidence of growth hormone deficiency (GHD) leading to growth failure and metabolic disorders. We aim to evaluate the benefits and risks of recombinant human growth hormone replacement therapy (GHRT) in postoperative children. Methods We retrospectively analyzed auxological and metabolic parameters and adverse events before and after GHRT of 44 children after CP surgery. Results The median duration of GHRT was 24 months (IQR, 12.5–36). Growth velocity (GV) increased significantly after different treatment duration (TD) compared with baseline (p<0.001) and attained the greatest GV of 12.06 ± 4.16 cm/year at TD6. The mean height standard deviation score (HtSDS) from −3.20 ± 1.16 at baseline improved significantly to −1.51 ± 1.32 at TD36 (p<0.001). There were significant increases in insulin-like growth factor-1 SDS (IGF-1SDS), insulin-like growth factor binding protein 3 SDS (IGFBP-3SDS), bone age (BA), and BA/chronological age (CA) (p<0.05). There was a significant reduction in waist-to-hip ratio (WHR), but there were no significant changes in weight SDS (WtSDS) or BMISDS. Low-density lipoprotein-cholesterol (LDL-C) levels and the incidence of hypercholesterolemia decreased (p<0.05). Three patients (6.8%) had tumor recurrence after 15, 30, and 42 months, respectively. A patient had residual tumor enlargement after 3 months. There was no adverse influence on glucose metabolism or any severe adverse events. Conclusions GHRT effectively accelerates GV, increases HtSDS, and improves lipid profiles without unfavorable effects on glucose metabolism. The benefits are clear and the risks of adverse events are low.
1 January 2025 in International Journal of Endocrinology
Introduction: Muscle function and strength are related to magnesium (Mg). The risk of low muscle mass in type 2 diabetes mellitus (T2DM) is higher compared to healthy individuals. This study aimed to evaluate the association between serum Mg and low muscle mass in people with T2DM. Methods: This study included 1074 inpatients with T2DM with measured skeletal muscle index (SMI) and serum Mg concentrations, along with collected clinical characteristics. SMI was measured using dual‐energy X‐ray absorptiometry. Logistic regression analysis and linear regression analysis were employed to examine the associations between serum Mg concentrations and low muscle mass or SMI, respectively. Results: The prevalence of low muscle mass was 20.28% in males and 14.20% in females. Serum Mg concentration was significantly higher in the low muscle mass group compared to the normal muscle mass group. Furthermore, among female patients with T2DM, a negative correlation was observed between Mg levels and SMI. Multivariate logistic regression analysis revealed that high Mg levels were significantly associated with an increased risk of low muscle mass. Specifically, in females, higher serum Mg levels significantly increased the risk of low muscle mass. The odds ratios (95% confidence intervals) across increasing tertiles (T1 to T3) of serum Mg were 1.00 (reference), 1.321 (95% CI, 0.626–2.790), and 2.071 (95% CI, 1.011–4.243), respectively, with a significant trend ( p for trend = 0.039). Conclusion: Low muscle mass in T2DM patients is associated with serum Mg levels. Notably, among female patients, higher serum Mg concentrations showed a significant linear trend and were negatively correlated with low muscle mass.